Baorui Liu
Nanjing University of Chinese Medicine(CN)China Pharmaceutical University(CN)Cancer Institute (WIA)(IN)Nanjing Drum Tower Hospital(CN)Jiangsu Cancer Hospital(CN)State Key Laboratory of Analytical Chemistry for Life ScienceNanjing University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Gastric Cancer Management and Outcomes, Cancer Genomics and Diagnostics, Cancer Research and Treatments
Most-Cited Works
- → Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study(2021)1,051 cited
- → Targeting VEGF/VEGFR to Modulate Antitumor Immunity(2018)613 cited
- → Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo(2015)355 cited
- → CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients(2016)302 cited
- → Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors(2019)224 cited
- → Successively activatable ultrasensitive probe for imaging tumour acidity and hypoxia(2017)209 cited